166 related articles for article (PubMed ID: 15846457)
41. The use of a pharmacophore model for identification of novel ligands for the benzodiazepine binding site of the GABAA receptor.
Kahnberg P; Howard MH; Liljefors T; Nielsen M; Nielsen EØ; Sterner O; Pettersson I
J Mol Graph Model; 2004 Dec; 23(3):253-61. PubMed ID: 15530821
[TBL] [Abstract][Full Text] [Related]
42. Epidermal growth factor and insulin short-term increase hPepT1-mediated glycylsarcosine uptake in Caco-2 cells.
Nielsen CU; Amstrup J; Nielsen R; Steffansen B; Frokjaer S; Brodin B
Acta Physiol Scand; 2003 Jun; 178(2):139-48. PubMed ID: 12780388
[TBL] [Abstract][Full Text] [Related]
43. Sterol regulatory element binding protein-mediated effect of fluvastatin on cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase transcription.
Mascaró C; Ortiz JA; Ramos MM; Haro D; Hegardt FG
Arch Biochem Biophys; 2000 Feb; 374(2):286-92. PubMed ID: 10666309
[TBL] [Abstract][Full Text] [Related]
44. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
Vyas VK; Ghate M; Goel A
J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
[TBL] [Abstract][Full Text] [Related]
45. Pharmacophore-based discovery of ligands for drug transporters.
Chang C; Ekins S; Bahadduri P; Swaan PW
Adv Drug Deliv Rev; 2006 Nov; 58(12-13):1431-50. PubMed ID: 17097188
[TBL] [Abstract][Full Text] [Related]
46. hPepT1-mediated epithelial transport of bacteria-derived chemotactic peptides enhances neutrophil-epithelial interactions.
Merlin D; Steel A; Gewirtz AT; Si-Tahar M; Hediger MA; Madara JL
J Clin Invest; 1998 Dec; 102(11):2011-8. PubMed ID: 9835627
[TBL] [Abstract][Full Text] [Related]
47. Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity.
Vyas VK; Qureshi G; Ghate M; Patel H; Dalai S
SAR QSAR Environ Res; 2016 Jun; 27(6):427-40. PubMed ID: 27310104
[TBL] [Abstract][Full Text] [Related]
48. Regulation of intestinal hPepT1 (SLC15A1) activity by phosphodiesterase inhibitors is via inhibition of NHE3 (SLC9A3).
Anderson CM; Thwaites DT
Biochim Biophys Acta; 2007 Jul; 1768(7):1822-9. PubMed ID: 17498647
[TBL] [Abstract][Full Text] [Related]
49. Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
Thondorf I; Voigt V; Schäfer S; Gebauer S; Zebisch K; Laug L; Brandsch M
Bioorg Med Chem; 2011 Nov; 19(21):6409-18. PubMed ID: 21955456
[TBL] [Abstract][Full Text] [Related]
50. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
51. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.
Jain V; Saravanan P; Arvind A; Mohan CG
Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830
[TBL] [Abstract][Full Text] [Related]
52. Transport of the advanced glycation end products alanylpyrraline and pyrralylalanine by the human proton-coupled peptide transporter hPEPT1.
Geissler S; Hellwig M; Zwarg M; Markwardt F; Henle T; Brandsch M
J Agric Food Chem; 2010 Feb; 58(4):2543-7. PubMed ID: 20104847
[TBL] [Abstract][Full Text] [Related]
53. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY
Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640
[TBL] [Abstract][Full Text] [Related]
54. Genomic structure of proton-coupled oligopeptide transporter hPEPT1 and pH-sensing regulatory splice variant.
Urtti A; Johns SJ; Sadée W
AAPS PharmSci; 2001; 3(1):E6. PubMed ID: 11741257
[TBL] [Abstract][Full Text] [Related]
55. In silico design of human IMPDH inhibitors using pharmacophore mapping and molecular docking approaches.
Li RJ; Wang YL; Wang QH; Wang J; Cheng MS
Comput Math Methods Med; 2015; 2015():418767. PubMed ID: 25784957
[TBL] [Abstract][Full Text] [Related]
56. Discovery of HIV-1 integrase inhibitors: pharmacophore mapping, virtual screening, molecular docking, synthesis, and biological evaluation.
Bhatt H; Patel P; Pannecouque C
Chem Biol Drug Des; 2014 Feb; 83(2):154-66. PubMed ID: 23957390
[TBL] [Abstract][Full Text] [Related]
57. Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
Vig BS; Stouch TR; Timoszyk JK; Quan Y; Wall DA; Smith RL; Faria TN
J Med Chem; 2006 Jun; 49(12):3636-44. PubMed ID: 16759105
[TBL] [Abstract][Full Text] [Related]
58. Novel butyrylcholinesterase inhibitors through pharmacophore modeling, virtual screening and DFT-based approaches along-with design of bioisosterism-based analogues.
Gogoi D; Chaliha AK; Sarma D; Kakoti BB; Buragohain AK
Biomed Pharmacother; 2017 Jan; 85():646-657. PubMed ID: 27903422
[TBL] [Abstract][Full Text] [Related]
59. Interaction of fluvastatin with the liver-specific Na+ -dependent taurocholate cotransporting polypeptide (NTCP).
Greupink R; Dillen L; Monshouwer M; Huisman MT; Russel FG
Eur J Pharm Sci; 2011 Nov; 44(4):487-96. PubMed ID: 21945488
[TBL] [Abstract][Full Text] [Related]
60. Development of a QSAR model for binding of tripeptides and tripeptidomimetics to the human intestinal di-/tripeptide transporter hPEPT1.
Andersen R; Jørgensen FS; Olsen L; Våbenø J; Thorn K; Nielsen CU; Steffansen B
Pharm Res; 2006 Mar; 23(3):483-92. PubMed ID: 16489544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
